推量调强放疗与常规放疗治疗ⅢB期非小细胞肺癌的临床疗效及安全性分析

Clinical efficacy and safety analysis of intensity-modulated radiotherapy and conventional radiotherapy for stage IIIB non-small cell lung cancer

目的对比分析同步推量调强放疗与常规放疗治疗非小细胞肺癌的临床效果及安全性。方法152例非小细胞肺癌患者随机分为对照组与观察组各76例,均予以放化疗联合治疗,化疗方案均为多西他赛+顺铂化疗(DP)方案,对照组予以常规放射疗法,观察组予以推量调强放射疗法。比较2组治疗的有效性、安全性及治疗前后患者肺癌肿瘤标志物的变化。结果观察组与对照组客观缓解率无统计学差异(P>0.05),观察组疾病控制率(94.74%)明显高于对照组(73.68%),差异有统计学意义(P<0.05)。观察组随访5年生存率、无进展生存期均优于对照组,差异有统计学意义(P<0.05);2组患者不良反应发生率差异无统计学意义(P>0.05)。治疗后,观察组血清肿瘤标志物Cyfra21-1、SCC、TSGF下降程度明显高于对照组,差异有统计学意义(P<0.05)。结论与常规放疗相比,同步推量调强放疗联合DP化疗可提高非小细胞肺癌患者疾病控制率,提高5年生存率,延长无进展生存时间。

Objective To compare the clinical efficacy and safety of intensity-modulated radiotherapy and conventional radiotherapy for non-small cell lung cancer.Methods A total of 152 patients with non-small cell lung cancer were randomly divided into a control group and an observation group,with 76 cases in each group.Both groups were treated with radiotherapy and chemotherapy.The chemotherapy regimen was docetaxel plus cisplatin chemotherapy(DP).The control group received conventional radiotherapy and the experimental group got intensity-modulated radiotherapy.The effectiveness and safety of the two groups and the changes of lung cancer markers before and after treatment were compared.Results There was no significant difference in the objective response rate between the two groups(P>0.05).The disease control rate of the observation group(94.74%)was higher than that(73.68%)of the control group(P<0.05).The 5-year survival rate and the progression-free survival of the observation group were better than those of the control group(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).The serum tumor markers Cyfra21-1,SCC and TSGF decreased in the observation group after treatment(P<0.05).Conclusions Compared with conventional radiotherapy,intensity-modulated radiotherapy combined with DP can improve the disease control rate and the 5-year survival rate of the patients with non-small cell lung cancer,and can prolong the progression-free survival time.